Addex Therapeutics Ltd.
Addex Therapeutics Ltd. (ADXN): ~9 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
2-factor signal · derived from public data
9.4 months
0% dilution
N/A
N/A
N/A
N/A
A transparent, data-derived signal for Addex Therapeutics Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$7.9M
Cash
$2.3M
Quarterly Burn
$769K
Runway
9.4 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3
Total value held
$3K
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 301 | $2K |
| gamma investing llc | 81 | $509 |
| rhumbline advisers | 72 | $450 |
Frequently asked questions
What is Addex Therapeutics Ltd.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Addex Therapeutics Ltd. has approximately 9.4 months of cash runway.
What is Addex Therapeutics Ltd.'s market capitalization?
Addex Therapeutics Ltd.'s market capitalization is approximately $7.9M.
Who is the CEO of Addex Therapeutics Ltd.?
Mr. Timothy Mark Dyer is the chief executive officer of Addex Therapeutics Ltd. (ADXN).
Get the full picture on Addex Therapeutics Ltd.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.